Related Content
Search Google Scholar for:
More Information
Related Jobs from ScienceCareers
|
|
Science 7 November 1997:
Vol. 278. no. 5340, pp. 1036 - 1039
DOI: 10.1126/science.278.5340.1036
|
|
News
CANCER RESEARCH:
From Bench Top to Bedside
Marcia Barinaga
More than 2 decades of research on oncogenes and tumor suppressors may finally pay off in a new generation of more specific, less toxic, cancer drugs. Some have already yielded promising results in cell culture studies and in animals, and are moving into tests in humans--and more are on the way. The targets of these drugs include cell surface receptors through which growth factors exert their effects and oncogene products that transmit growth-stimulatory signals inside cells. Still others aim to compensate for oncogene or tumor-suppressor gene mutations that impair cells' ability to initiate programmed cell death or apoptosis. Researchers hope these new therapies will kill cancer cells more effectively, with less harm to normal cells.
Read the Full Text
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin's Lymphoma Severe Combined Immunodeficiency Mouse Model.
- F. J. Hernandez-Ilizaliturri, V. Jupudy, J. Ostberg, E. Oflazoglu, A. Huberman, E. Repasky, and M. S. Czuczman (2003)
Clin. Cancer Res.
9, 5866-5873
| Abstract »
| Full Text »
| PDF »
- Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors.
- R. W. Wilkinson, E. L. Ross, R. Poulsom, M. Ilyas, J. Straub, D. Snary, W. F. Bodmer, and S. J. Mather (2001)
PNAS
| Abstract »
| Full Text »
| PDF »
- Farnesyltransferase Inhibitor Induces Rapid Growth Arrest and Blocks p70s6k Activation by Multiple Stimuli.
- B. K. Law, P. Norgaard, and H. L. Moses (2000)
J. Biol. Chem.
275, 10796-10801
| Abstract »
| Full Text »
| PDF »
- A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors.
- K. Del Villar, J. Urano, L. Guo, and F. Tamanoi (1999)
J. Biol. Chem.
274, 27010-27017
| Abstract »
| Full Text »
| PDF »
- DNA Damage Increases Sensitivity to Vinca Alkaloids and Decreases Sensitivity to Taxanes through p53-dependent Repression of Microtubule-associated Protein 4.
- C. C. Zhang, J.-M. Yang, J. Bash-Babula, E. White, M. Murphy, A. J. Levine, and W. N. Hait (1999)
Cancer Res.
59, 3663-3670
| Abstract »
| Full Text »
| PDF »
- Signaling Inhibitors in the Clinic: New Agents and New Challenges.
- G. Hudes (1999)
J. Clin. Oncol.
17, 1093
| Full Text »
| PDF »
- Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells.
- N. Suzuki, J. Urano, and F. Tamanoi (1998)
PNAS
95, 15356-15361
| Abstract »
| Full Text »
| PDF »
- Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents.
- N. Suzuki, K. Del Villar, and F. Tamanoi (1998)
PNAS
95, 10499-10504
| Abstract »
| Full Text »
| PDF »
- Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans.
- K. Ruckemann, L. D. Fairbanks, E. A. Carrey, C. M. Hawrylowicz, D. F. Richards, B. Kirschbaum, and H. A. Simmonds (1998)
J. Biol. Chem.
273, 21682-21691
| Abstract »
| Full Text »
| PDF »
- Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors.
- R. W. Wilkinson, E. L. Ross, R. Poulsom, M. Ilyas, J. Straub, D. Snary, W. F. Bodmer, and S. J. Mather (2001)
PNAS
98, 10256-10260
| Abstract »
| Full Text »
| PDF »
|
|
